NCT06376916

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Atrial Tachycardia Reduction With Intravenous Use of Magnesium (ATRIUM) Study: Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 153 (estimated)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.

Detailed description

Intravenous magnesium has become a commonly utilized agent in the treatment of cardiac arrhythmias as an adjunct therapy to rate and rhythm control medications, such as its use in atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR). Though its benefit in the treatment of AFF RVR has been well documented, a consensus on the optimal dosing of magnesium has yet to be achieved. Only one randomized, controlled, double-blinded study has investigated the optimal dosing of magnesium.

Conditions

• Tachycardia Atrial
• Atrial Fibrillation
• Atrial Flutter With Rapid Ventricular Response

Interventions

Type	Name	Description
DRUG	Magnesium Sulfate 2 G	Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
DRUG	Magnesium Sulfate 4 G	Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
DRUG	Saline	The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.

Timeline

• Start date: 2024-10-07
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2024-04-22
• Last updated: 2025-10-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study